Table 2 Association between MET and PD-L1 expressions and clinicopathological characteristics in PDAC patients
From: Combinational blockade of MET and PD-L1 improves pancreatic cancer immunotherapeutic efficacy
Characteristics | MET and PD-L1 | MET and PD-L1 | P value |
|---|---|---|---|
low expression (N = 44) | high expression (N = 49) | ||
Gender | 0.523 | ||
Male | 28 (50 %) | 28 (50 %) | |
Female | 16 (42.1 %) | 21 (57.9 %) | |
Age | 0.432 | ||
≤ 60 years | 14 (53.8 %) | 12 (46.2 %) | |
> 60 years | 30 (44.8 %) | 37 (55.2 %) | |
BMI | 0.664# | ||
< 18.5 | 4 (40 %) | 6 (60 %) | |
18.5–23.9 | 31 (50.8 %) | 30 (49.2 %) | |
> 23.9 | 9 (40.9 %) | 13 (59.1 %) | |
Tumor location status | 0.127 | ||
Head and neck | 35 (52.2 %) | 32 (47.8 %) | |
Body and tail | 9 (34.6 %) | 17 (65.4 %) | |
Tumor size status | 0.501# | ||
≤ 2 cm | 5 (50 %) | 5 (50 %) | |
2 < n ≤ 4 cm | 32 (50.8 %) | 31 (49.2 %) | |
> 4 cm | 7 (35 %) | 13 (65 %) | |
Lymph nodes involvement | 0.034 | ||
No | 21 (61.8 %) | 13 (38.2 %) | |
Yes | 23 (39 %) | 36 (61 %) | |
TNM stage | 0.020# | ||
I | 15 (75 %) | 5 (25 %) | |
II | 27 (39.7 %) | 41 (60.2 %) | |
III-IV | 2 (40 %) | 3 (60 %) | |
Tumor differentiation | 0.869# | ||
Well differentiated | 9 (60 %) | 6 (40 %) | |
Moderately differentiated | 18 (42.9 %) | 24 (57.1 %) | |
Poorly differentiated | 17 (47.2 %) | 19 (52.8 %) | |
CA199 | 0.575 | ||
≤ 37 | 7 (41.2 %) | 10 (58.8 %) | |
> 37 | 37 (48.7 %) | 39 (51.3 %) | |
CA125 | 0.597 | ||
≤ 35 | 33 (45.8 %) | 39 (54.2 %) | |
> 35 | 11 (52.4 %) | 10 (47.6 %) | |
CEA | 0.196 | ||
≤ 5 | 30 (52.6 %) | 27 (47.4 %) | |
> 5 | 14 (38.9 %) | 22 (61.1 %) |